BioCentury
ARTICLE | Clinical News

Laquinimod: Phase II started

May 4, 2015 7:00 AM UTC

Teva began the double-blind, placebo-controlled, international Phase II ARPEGGIO trial to evaluate 0.6 and 1.5 mg oral laquinimod once daily in about 375 patients. Teva has exclusive, worldwide rights...